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Summary
 
Gene modification of hematopoietic stem cells (HSC) with antigen-specific, chimeric, or “uni-
versal” immune receptors (URs) is a novel but untested form of targeted immunotherapy. A
human immunodeficiency virus (HIV) envelope–specific UR consisting of the extracellular
domain of human CD4 linked to the 
 
z
 
 chain of the T cell receptor (CD4
 
z
 
) was introduced ex
vivo into murine HSC by retroviral transduction. After transplantation into immunodeficient
SCID mice, sustained high level expression of CD4
 
z
 
 was observed in circulating myeloid and
natural killer cells. CD4
 
z
 
-transplanted mice were protected from challenge with a lethal dose of
a disseminated human leukemia expressing HIV envelope. These results demonstrate the ability
of chimeric receptors bearing 
 
z
 
-signaling domains to activate non–T cell effector populations
in vivo and thereby mediate systemic immunity.
 
I
 
ntroduction of therapeutic genes into hematopoietic
stem cells (HSC)
 
1
 
 may be useful for treatment of human
diseases such as HIV infection and cancer. Current gene
therapy strategies for AIDS include “intracellular immuni-
zation” (1) in which inhibition of HIV infection or propa-
gation in target cells is mediated through the introduction
of HIV resistance genes into HSC or mature T cells (2–4),
as well as active immunization with gene-modified cells
expressing HIV antigens (5, 6). Strategies for cancer gene
therapy include active immunization with autologous tu-
mor cells genetically altered ex vivo with immunomodula-
tory genes, such as costimulatory receptors and cytokines
(7, 8). Many of these approaches rely on active as opposed
to passive immunotherapy, requiring in vivo stimulation of
the host cellular immune system and induction of T cell re-
sponses to achieve effective systemic immunity.
In this report, we describe a novel strategy for passive
immunotherapy of infectious or malignant disease involv-
ing transplantation of HSC modified ex vivo with disease-
specific chimeric or “universal” immune receptors. Universal
receptors (UR) are HLA-unrestricted chimeric proteins in
which the signaling domain of a native immune receptor is
fused to a heterologous ligand-binding domain. Cytolytic
effectors such as myeloid and NK cells arise rapidly after
bone marrow transplantation, and can be specifically di-
rected via URs to diseased cells in vivo. Furthermore, gene-
modified HSC provide a continuous source of UR-expressing
hematopoietic cells of multiple lineages, which may lead to
prolonged systemic immunity.
To date, reports from our laboratory and others have ex-
amined in vitro UR function after modification of mature
T (9–13) and NK (14) cells. We have previously described
two classes of UR in which the signaling domain of the
TCR-
 
z
 
 chain (15, 16) is fused either to a single-chain anti-
body (SAb) specific for the HIV envelope (HIV-env) gly-
coprotein, gp41, or to the extracellular domain of human
CD4 specific for HIV-env gp120. Both receptors redirect
CD8
 
1
 
 T cells (13) and NK cells (14) to kill HIV-infected
cells and HIV-env–expressing tumors in vitro. Although
the native 
 
z
 
 chain is primarily associated with the TCR,
the cytoplasmic tails of the Fc receptor (FcR)-
 
g
 
 chain and
TCR-
 
z
 
 share a conserved 18–amino acid immunoreceptor
tyrosine activation motif (17, 18), and both 
 
g
 
 and 
 
z
 
 are
present as homo- and heterodimers in some classes of FcR
(19–21). This structural similarity suggests that 
 
z
 
-bearing
URs may also activate FcR-mediated effector functions of
myeloid cells, such as antibody-dependent cellular cytotox-
icity (ADCC). Indeed, preliminary work in this laboratory
demonstrates cytolytic activity of CD4
 
z
 
-expressing neutro-
phils against HIV-env–expressing target cells in vitro (our
 
1
 
Abbreviations used in this paper:
 
 ADDC, antibody-dependent cytotoxicity;
APC, allophycocyanin-streptavidin; FcR, Fc receptor; HIV-env, HIV
envelope; HSC, hematopoietic stem cells; LDC, low density cells; PB,
peripheral blood; Raji-env, Raji cells expressing HIV-env; SAb, single-
chain antibody.
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unpublished data). To analyze the in vivo function of non–T
cell effector populations bearing 
 
z
 
-based URs, we trans-
planted immunodeficient SCID mice that lacked mature T
and B cells (22, 23) with bone marrow that were retrovi-
rally-transduced with the CD4
 
z
 
 UR. Transplanted mice
were analyzed for UR expression and subsequently chal-
lenged with a human B cell leukemia stably expressing
HIV-env.
 
Materials and Methods
 
Retroviral Vectors.
 
The retroviral vector rkat43.3F3 is a variant
of the previously described rkat43.2F3 vector (24) in which an
internal human phosphoglycerol kinase (PGK) promoter has been
inserted upstream of the CD4
 
z
 
 coding sequence. Retroviral su-
pernatants were prepared by transient transfection of human 293
cells with rkat43.3F3 and a plasmid containing packaging func-
tions (pkat) using the 
 
kat
 
 system (24).
 
HIV-specific CD4 and SAb URs.
 
The CD4
 
z
 
 UR was con-
structed as described previously (13). The HIVgp120-specific SAb
 
z
 
UR was constructed as described for the HIVgp41-specific SAb
 
z
 
UR (13), with the following modification: the extracellular do-
main of the gp120-SAb
 
z
 
 UR was derived from the gp120-spe-
cific human mAb, 447-D (25). The cytoplasmic and transmem-
brane domains are identical to that of CD4
 
z
 
, deriving from
TCR
 
z
 
 and CD4, respectively.
 
Animals.
 
C.B-17 
 
scid
 
/
 
scid
 
 (SCID) mice were used for all
transplant studies. Bone marrow donors were 8–16-wk-old male
and female mice obtained from the Cell Genesys in-house SCID
colony. Bone marrow recipients were 8–12-wk-old male SCID
mice procured from an outside vendor (Charles River Laborato-
ries, Wilmington, MA). Animals were housed in sterile laminar
airflow hoods and fed ad lib with sterile food and water. Before
use in transplantation experiments, mice were screened for serum
IgM levels by ELISA as previously described (26). Only mice
with 
 
,
 
0.5 
 
m
 
g/ml IgM were used. All animal procedures con-
formed to institutional guidelines.
 
Retroviral Transduction and Transplantation of SCID Mice.
 
Donor
SCID mice were injected via the tail vein with 5-fluorouracil
(100 
 
m
 
g/kg; Roche Laboratories, Hoffmann-La Roche Inc., Nutley,
NJ). 6 d later, mice were killed by CO
 
2
 
 asphyxiation. Femurs
were harvested and flushed with culture medium (DME/4.5 g/li-
ter glucose, 15% FCS, glutamine, penicillin, and streptomycin) 
 
1
 
 5
mM EDTA. Low density cells (LDC) were isolated by density
gradient separation using Lympholyte-M (Cedarlane Laboratories
Ltd., Hornby, Ontario, Canada). Briefly, bone marrow cells were
layered over an equal volume of gradient and spun at 2,200 rpm
for 20 min at 20
 
8
 
C in a tabletop centrifuge. Interphase cells were
collected, washed, and resuspended in culture media. LDC were
plated at 3 
 
3
 
 10
 
6
 
 cells/well of a six-well plate (Corning Glass Inc.,
Corning, NY) and exposed to UR-expressing retroviral supernatant
(CD4
 
z
 
 or SAb
 
z
 
) containing 8 
 
m
 
g/ml polybrene on plates coated
with rat fibronectin (15 mg/well of six-well plate in PBS; Sigma
Immunochemicals, St. Louis, MO; 27). After 2 h, the medium was
hemidepleted and fresh viral supernatant was added. Viral super-
natant was prepared by transfection of 293 cells using the 
 
kat
 
 system,
as described previously (24). Transduced cells were harvested from
the plates after 4 h, washed, and resuspended in 0.9% NS 
 
1
 
 0.1%
BSA for injection. 10
 
6
 
 transduced LDC/mouse were infused into
sublethally irradiated (350 rads) SCID mice via tail vein injection.
 
Immunofluorescence Analysis of CD4
 
z
 
.
 
300 
 
m
 
l of heparinized
blood was attained by retroorbital bleeds of CD4
 
z
 
 transplanted
and control mice at various time points after transplant. RBCs were
depleted by ammonium chloride lysis. Approximately 2 
 
3
 
 10
 
5
 
cells/stain were incubated with the following murine-specific
mAbs conjugated to FITC: anti–GR-1, anti–Mac-3, anti-5E6
(Pharmingen, San Diego, CA) in addition to anti–human CD4-PE
(Becton Dickinson & Co., Mountain View, CA), according to
manufacturer’s instructions. FITC- and PE-conjugated isotype-
matched mAbs served as negative controls. Stained cells were an-
alyzed on a FACScan
 
Ò
 
 cytometer (Becton Dickinson).
 
Quantitative-Competitive PCR Assay for CD4
 
z
 
.
 
20,000 RBC-
depleted peripheral blood cells isolated from CD4
 
z
 
-transplanted
mice (e
 
2
 
) were combined with known titrations of transduced
competitor cells in which the CD4
 
z
 
 construct contained an addi-
tional 102-bp insert comprised of the 3
 
9
 
 end of the Moloney mu-
rine leukemia virus envelope gene (e
 
1
 
). Cell mixtures were
washed, resuspended in 50 
 
m
 
l of lysis buffer (1
 
3
 
 PCR buffer
(Fisher Scientific, Pittsburgh, PA), 0.1% Tween 20, 100 
 
m
 
g/ml
proteinase K (Boehringer Mannheim, Indianapolis, IN) and
heated to 55
 
8
 
C for 45 min, followed by 95
 
8
 
C for 15 min. PCR
was performed using a primer set that recognizes the integrated
CD4-
 
z
 
 construct (upper, 5
 
9
 
AACTGATTGGTTAGTTCAAAT-
AAGGC3
 
9
 
; lower, 5
 
9
 
CCAGACCTGCAGACGCCCAGA3
 
9
 
). 2 
 
m
 
l
of cell lysate was added to 48 
 
m
 
l of PCR reaction mix (25 pmol
each primer, 1
 
3
 
 PCR buffer, 1.5 mM MgCl
 
2
 
, 5 U Taq poly-
merase [Fisher], 50 
 
m
 
M dNTP). Cycling was initiated in a ther-
mocycler (model 9600; Perkin-Elmer Corp., Norwalk, CT,
94
 
8
 
C for 30 s, 60
 
8
 
C for 30 s, 72
 
8
 
C for 30 s, 26 cycles). The PCR
products were electrophoresed through preformed 6% polyacryl-
amide gels (Novex, San Diego, CA) and resolved by autoradiog-
raphy.
 
PCR Assay for Detection of Raji Cells Expressing HIV-env.
 
300 
 
m
 
l
of heparinized peripheral blood (PB) was attained by retroorbital
bleeds from eight surviving mice 4 mo after Raji cells expressing
HIV-env (Raji-env) challenge and a control mouse. Ammonium
chloride RBC lysis was performed and recovered cells were washed,
pelleted, and resuspended at 2,000 cell/
 
m
 
l in lysis buffer (1
 
3
 
 PCR
buffer [Fisher], 0.1% Tween 20, and 100 
 
m
 
g/ml proteinase K [Boeh-
ringer Mannheim]). As a positive control, lysates of 0.1, 1, and 10
cultured Raji-env cells in a background of 10
 
4
 
 NIH 3T3 cells were
also prepared. The samples were heated at 55
 
8
 
C for 45 min, followed
by 95
 
8
 
C for 15 min to inactivate the proteinase K. PCR was then
performed using two sets of primers: (
 
a
 
) murine 
 
b
 
-actin (upper
5
 
9
 
CGAGCATCCCCCAAAGTTCA-CAA3
 
9
 
; lower 5
 
9
 
CCCAGC-
CACACCACAAAGTCACA3
 
9
 
) and (
 
b
 
) herv-H (upper 5
 
9
 
ACT-
ATAGGCAACTTTCCACC-CTCC3
 
9
 
; lower 5
 
9
 
GCTACTTGG-
CTGCCT-CTA-CTCTA3
 
9
 
). Reactions were set up in a 50-
 
m
 
l
vol with 5 
 
m
 
l of cell lysate, 1
 
3
 
 PCR buffer, 1.5 mM MgCl
 
2
 
, 25
pmol of each primer, 50 
 
m
 
M dNTP, and 5 U Taq polymerase
(Fisher). Cycling was initiated in a Perkin-Elmer thermocycler
(94
 
8
 
C for 1 min, 60
 
8
 
C for 1 min, 72
 
8
 
C for 2 min, 30 cycles). The
PCR products were electrophoresed through preformed 6%
polyacrylamide gels (Novex) and resolved by autoradiography.
 
Recovery of Raji-env from Transplanted Mice.
 
At the time of death
from disseminated leukemia, femoral bone marrow was harvested
from a CD4
 
z
 
-transduced and a control mouse injected with Raji-
env. Bone marrow cells were subjected to ammonium chloride
RBC lysis and then incubated with saturating concentrations of
anti–human CD19-PE (Becton Dickinson) for detection of Raji-
env cells. CD19
 
1
 
 Raji-env cells were then sorted using the Bec-
ton Dickinson FACStar Plus
 
Ò
 
. Recovered cells were subjected to
flow cytometric and immunoblot analysis to detect the HIV-env
protein gp120.
 
Immunofluorescence Analysis of Raji-env.
 
106 sorted Raji-env cells,2263 Hege et al.
as well as parental Raji cells (Raji-p) and Raji-env cells maintained
in liquid culture, were incubated with mouse anti-gp120 mAb
(New England Nuclear [NEN] Virus Research, Wilmington,
DE) or the isotype-negative control, followed by incubation with
goat anti–mouse biotin F(ab9)2 (Cappel Laboratories, Durham,
NC) and allophycocyanin-streptavidin (APC; Molecular Probes,
Inc., Eugene, OR). APC-stained cells were analyzed using a Bec-
ton Dickinson FACStar PlusÒ.
Immunoblot Analysis of Raji-env. 106 sorted Raji-env cells and
cultured Raji-p and Raji-env cells were lysed for 30 min at 48C
in 10 ml of NP-40 lysis buffer (1% NP-40, 150 mM NaCl, and 10
mM Tris [pH 7.8]). Lysates were subjected to SDS-PAGE, trans-
ferred to nitrocellulose membranes, and incubated with anti-
gp120 mAb (NEN Virus Research). Bound Ab was detected
with horseradish peroxidase–conjugated sheep Ab to mouse IgG,
followed by a nonisotopic enhanced chemiluminescence assay
(Amersham, Arlington Heights, IL).
Neutrophil Isolation and Cytotoxicity Assay. 3 wk after trans-
plant, four CD4z-transduced and four control mice were treated
with seven daily subcutaneous injections of human G-CSF (100
mg/kg per d; Amgen, Thousand Oaks, CA). Mice were then
killed, and heparinized blood was recovered by cardiac puncture.
Neutrophils were isolated using a modification of the standard
“1-step Polymorph” procedure (Accurate Chemical & Science
Corp., Westbury, NY) (28) in which 0.8 ml of 1.5% NaCl was
added to 10 ml of stock gradient. 4 ml of murine PB was layered
over 4 ml of modified gradient, and tubes were spun for 30 min
at 450 g at 208C in a tabletop centrifuge. The neutrophil fraction
was recovered and washed twice. An aliquot was removed for
cytospin analysis and Wright-Giemsa staining using standard
techniques. Additional cells were removed for measurement of
CD4z transduction efficiency by flow cytometric and quantita-
tive-competitive (QC)-PCR analysis. The remaining cells were
used in a chromium release cytotoxicity assay. Raji-p and Raji-
env cells were labeled with sodium [51Cr] chromate (100 mCi/
106 cells) for 3 h at 378C, washed three times, and resuspended in
assay medium (RPMI, 10% FCS, 10 ng/ml murine GM-CSF).
105 51Cr-labeled target cells were plated in duplicate in 96-well
plates together with control or CD4z-expressing neutrophils at
E/T ratios of 250:1–1.2:1. To measure ADCC, polyclonal rabbit
anti–human lymphocyte serum (4 mg/ml; Accurate Chemical &
Science Corp.) was added to one row of duplicate wells. Cells were
incubated at 378C for 4 h. 100 ml of supernatant was removed
from each well and counted in a gamma counter for the assessment
of 51Cr release. The percentage of specific lysis was calculated from
duplicate samples using the following formula: (CMP 2 SR)/
(MR 2 SR) 3 100, where CMP is the cpm released by targets
incubated with effector cells, MR is the cpm released by targets
lysed with 100 ml of 1% Triton X-100, and SR is the cpm re-
leased by targets incubated with medium only.
Results
Transplantation of SCID Mice with CD4z-modified Bone
Marrow. The UR CD4z was introduced into bone mar-
row progenitor cells of SCID mice using retroviral trans-
duction. A high efficiency retroviral transduction system,
kat, was used to generate high titer retroviral supernatants
containing the CD4z construct from 293 cells transiently
transfected with packaging (pkat) and retroviral vector
(rkat) plasmids, as described previously (24). Retroviral ti-
ters on NIH 3T3 cells ranged from 6 3 106–107 viral parti-
cles/ml. The retroviral vector used, rkat43.3F3, is Moloney
murine leukemia virus based and contains an internal phos-
phoglycerol kinase (PGK) promoter to minimize loss of
transcriptional activity in vivo (29). After reverse transcrip-
tion and integration into target cells, transcription is initi-
ated only from the PGK promotor. Previous work in this
laboratory has shown that this vector yields stable levels of
CD4z expression over 6 mo in transplanted C3H mice,
whereas viral long terminal repeat (LTR) driven expression
diminishes rapidly over 1–2 mo (our unpublished data).
Donor SCID mice were treated with 5-fluorouracil to
enrich for immature hematopoietic progenitors with long-
term repopulating ability (30). LDC were isolated and ex-
posed to CD4z retroviral supernatant in the presence of rat
fibronectin, which has been shown to increase the effi-
ciency of retroviral gene transfer (27). Transduced cells
were then infused via tail vein injection into sublethally ir-
radiated recipient SCID mice.
Sustained, Multilineage Expression of CD4z in Transplanted
Mice. Long-term multilineage in vivo expression of the
CD4z UR was achieved after gene transfer into SCID
bone marrow. 3 wk after transplant, mice were analyzed
for transduction efficiency and CD4z expression by QC-
PCR and flow cytometric analysis of peripheral blood and
bone marrow. In five separate experiments using 20–40
mice each, the mean percentage of PB leukocytes express-
ing CD4z as measured by immunofluorescence was 39%
(range 5 12–70%). Lineage-specific expression of CD4z
was measured by double staining with PE-conjugated anti–
human CD4 and FITC-conjugated mAbs specific for vari-
ous murine blood lineages (Fig. 1 a). These included Mac-3
(found on monocytes, macrophages, and granulocytes; 31),
Gr-1 (expressed on granulocytes; 32), and 5E6 (present on
a subset of NK cells; 33). CD4z expression was highest in
Mac-31 monocytes and granulocytes, followed by Gr-1
bright mature granulocytes, and 5E61 NK cells. The ab-
sence of circulating CD41 and CD81 T cells in these trans-
planted SCID mice was confirmed by flow cytometry (data
not shown). The percentage of bone marrow cells express-
ing CD4z averaged 20–40% of that seen in the PB, sug-
gesting that expression of CD4z in hematopoietic cells may
be affected by their state of differentiation.
Subsequent QC-PCR analysis of PB from five trans-
planted mice demonstrated levels of integrated provirus
that approximated expression levels determined by immu-
nofluorescence. A representative result is shown in Fig. 1, b
and c. To confirm that our transduction system targeted
long-term repopulating HSC (34), CD4z expression in the
peripheral blood of transplanted mice was monitored dur-
ing a period of 6 mo. In a cohort of eight mice followed
longitudinally, the mean percentage of peripheral blood
leukocytes expressing CD4z, as measured by immunofluo-
rescence, was 16% (range 5 13–19%) at 3 wk, 14% (range 5
6–23%) at 4 mo, and 17% (range 5 5–28%) at 6 mo.
CD4z-expressing Mice Demonstrate Immunity to Raji-env.
We next tested the in vivo function of hematopoietic cells
expressing CD4z by challenging transplanted mice with a
derivative of the human B cell leukemia/lymphoma, Raji,2264 Tumor Immunity in SCID Mice with Gene-modified Bone Marrow
which stably expresses low levels of the HIV-env proteins
gp120 and gp41 (Raji-env; 14). Since HIV gp120 binds to
human CD4, Raji-env is a specific target for the CD4z
UR. Intravenous infusion of Raji-p into SCID mice repro-
ducibly causes a lethal disseminated leukemia that invades
the bone marrow, liver, spleen, and central nervous system
(26). Preliminary studies were performed to determine the
optimal tumor dose for subsequent challenge experiments.
Deaths after intravenous infusion of various doses of either
Raji-p or Raji-env were as follows: 107 (17–22 d), 106 (22–
25 d), 105 (30–60 d), 104 (no deaths).
In the first experiment, SCID mice were transplanted
with CD4z-transduced bone marrow, and 3 wk later were
challenged with 105 or 106 Raji-p or Raji-env cells via tail
vein injection. Transplanted mice were then followed for
the development of hind leg paralysis secondary to central
nervous system invasion and death from disseminated leu-
kemia (Fig. 2 a). In the group receiving 105 Raji-env cells,
8/10 CD4z-expressing mice survived .4 mo after trans-
plant, whereas only 1/10 of the transplanted mice receiving
105 Raji-p cells survived (Fig. 2 a). All untransplanted mice
challenged with either Raji-p or Raji-env died within 60 d.
Figure 1. Analysis of CD4z ex-
pression in transplanted mice. (a)
Flow cytometric analysis. PB leuko-
cytes from mice 3 wk after transplant
were incubated with the following
murine-specific mAbs conjugated to
FITC: anti–GR-1, anti–Mac-3,
anti-5E6 in addition to anti–human
CD4-PE. Background human CD4
expression in various lineages in a
control mouse (top) is compared to
human CD4 expression in a CD4z
transplanted mouse (bottom). Spe-
cific cell staining was measured on
gated populations containing mye-
loid cells (Gr-1 and Mac-3) and
lymphoid cells (NK5E6), as deter-
mined by forward and side scatter
characteristics. Results are represen-
tative of those observed in 80 addi-
tional mice. (b) QC-PCR analysis.
CD4z-expressing PB cells from a
mouse 3 wk after transplant (e2)
were combined with known titra-
tions of CD4z-transduced competi-
tor cells (e1). The lane in which the
e2 and e1 amplification products are
equivalent represents the percentage
of PB cells containing the CD4z
gene; in this case, z10%. The corre-
sponding expression level by FACSÒ
analysis in this mouse was 20%. PB
from an untransplanted mouse serves
as a control. (c) The structure of the
integrated CD4z retroviral vector
and the competing template used in
the QC-PCR assay. The CD4z
construct used to generate the e1
competitor cells contains an addi-
tional 102-bp sequence to enable
differential separation of the PCR
products on gel electrophoresis.
The location of the PCR primers
(black arrows) and the expected com-
peting transcripts (e2 and e1) are
shown.  PGK, human phosphoglyc-
erate kinase promoter.2265 Hege et al.
At the higher leukemia cell dose of 106, CD4z-expressing
mice receiving Raji-env exhibited a 10–40-d delay in
death as compared to Raji-p infused controls, but 9/10
mice died within 80 d (data not shown).
Similar results were observed in a second experiment de-
signed to test the limits of this model by comparing the anti
tumor activity mediated by a high versus a low expressing
UR. Murine bone marrow was transduced with either the
CD4z UR or with a SAbz UR specific for HIV-env gp120
which, in contrast to previous SAbz URs tested (13), is
poorly expressed upon gene transfer. CD4z-transduced
mice showed surface human CD4 expression in 29–42% of
circulating leukocytes at 3 wk after transplant, whereas
mice transplanted with the SAbz gene expressed the UR in
only 1–3% of peripheral blood cells by flow cytometry (data
not shown). CD4z, SAbz, and untransplanted control mice
were challenged with 105 Raji-p or Raji-env cells (five per
group, Fig. 2 b). 4/5 CD4z-expressing mice that received
Raji-env cells survived .4 mo after infusion. In contrast,
all five SAbz-transplanted mice succumbed to the dissemi-
nated Raji-env leukemia, as did 9/10 control untrans-
planted mice challenged with either Raji-p or Raji-env,
and all CD4z- and SAbz-transplanted mice receiving Raji-p.
This study confirms the in vivo antitumor activity of
Figure 2. Survival of transplanted mice after Raji-env cell infusion. In
two separate experiments, SCID mice were transplanted with UR-trans-
duced bone marrow (CD4z or SAbz). 3 wk after transplant, UR-trans-
Figure 3. Death of CD4z-transplanted mice after Raji-env infusion is associated with a loss of gp120 expression in vivo. (a) Flow cytometric analysis.
Raji-env cells sorted from the bone marrow of a CD4z-transplanted (CD4z sort) and a control mouse (control sort), as well as Raji-p and Raji-env cells
maintained in liquid culture, were incubated with mouse anti-gp120 mAb to detect surface expression of HIV-env or the isotype-negative control, fol-
lowed by incubation with goat anti–mouse biotin F(ab9)2 and APC (Molecular Probes). (b) Immunoblot analysis. Sorted Raji-env cells (CD4z sort and
control sort) and cultured Raji-p and Raji-env cells were lysed and subjected to SDS-PAGE, followed by immunoblotting with anti-gp120 mAb to detect
the presence of the env protein.
duced and control mice were injected via the tail vein with Raji-p or
Raji-env tumor cells. (a) Survival of CD4z mice (10/group) receiving 105
Raji-env (CD4z1R-env) or Raji-p (CD4z1R-p) cells compared to his-
torical control untransplanted mice (5/group) receiving 105 Raji-env
(ctrl1R-env) or Raji-p (ctrl1R-p) cells. Between 4 and 8 mo after trans-
plant, four of the Raji-env survivors died from the spontaneous develop-
ment of endogenous thymic lymphomas, which is a known complication
of sublethal irradiation in SCID mice (51). (b) Survival of CD4z and SAbz
mice (5/group) challenged with 105 Raji-env or Raji-p cells compared
with concurrent control untransplanted mice infused with either tumor
(5/group). SAbz mice infused with 105 Raji-p all died within 50 d.2266 Tumor Immunity in SCID Mice with Gene-modified Bone Marrow
CD4z-bearing hematopoietic cells seen in the first experi-
ment and shows a relative lack of SAbz UR–mediated ac-
tivity, which is likely secondary to low in vivo expression
levels. Furthermore, this study rules out the possibility that
survival of the CD4z mice challenged with Raji-env is
caused by a nonspecific effect of the radiation or transplant
regimen.
Outgrowth of Env2 Raji Revertants in Vivo. In the first
experiment, it was noted that death was delayed in the two
CD4z-expressing mice that died after challenge with 105
Raji-env cells (Fig. 2 a). To assay for the maintenance of
gp120 expression by Raji-env in vivo, bone marrow was
harvested from one of these mice at the time of death, and
Raji-env cells were isolated by cell sorting using the human
anti-B cell mAb anti–Leu-12 (CD19). Human CD191 Raji
cells constituted 4% of bone marrow leukocytes at the time
of death from disseminated leukemia in this mouse. Re-
covered Raji-env cells were subjected to a sensitive APC
staining procedure to detect surface expression of HIV
gp120 (Fig. 3 a), as well as immunoblot analysis to detect
total protein (Fig. 3 b). HIV gp120 could not be detected
in these cells by either technique, suggesting that delayed
death of this animal resulted from the outgrowth of Raji-
env2 revertants. In contrast, Raji-env cells sorted from the
bone marrow of a control mouse at the time of death
maintained stable expression of HIV gp120 by both flow
cytometric and immunoblot analyses (Fig. 3, a and b). In
subsequent experiments, death after infusion of 105 Raji-
env cells into CD4z-transplanted mice was associated with
a loss of gp120 expression in three out of three mice ana-
lyzed.
Absence of Detectable Raji-env in Surviving Mice. To screen
for residual circulating leukemia cells in surviving CD4z-
expressing mice challenged with Raji-env, PCR analysis
was carried out on PB 4 mo after transplant (Fig. 4). The
PCR assay used a probe specific for a human endogenous
retroviral sequence, Herv-H, which is present in multiple
copies in all human cells (35, 36). The sensitivity of this as-
say is sufficient to detect a single Raji cell in a background
of 105 murine cells. All surviving mice were PCR negative,
ruling out the presence of minimal residual disease at this
level of detection.
In Vitro Neutrophil Cytotoxicity. Previous studies from our
laboratory have shown that z-bearing URs can direct the
cytolytic activity of FcR-bearing nonlymphoid effector
cells such as NK cells in vitro (14). Since 70–80% of circu-
lating leukocytes in the SCID mouse are neutrophils (23),
we sought to determine whether neutrophils harvested
from UR-transplanted SCID mice could demonstrate tu-
mor-specific cytolytic activity in vitro. In three separate ex-
periments, neutrophils isolated from the peripheral blood
of CD4z-expressing mice demonstrated low level but spe-
cific cytolysis of Raji-env targets in a chromium release cy-
totoxicity assay. One representative experiment is shown in
Fig. 5. After correction of the E/T ratio for the percentage
of CD4z-expressing cells in the bulk neutrophil population
(i.e., 8%), UR-mediated target cell lysis approached FcR-
mediated ADCC. Because of limitations in the absolute
number of CD4z-expressing neutrophils that could be iso-
lated from these mice, and the observation that neutrophil
ADCC is optimal at E/T ratios in excess of 100:1 (37–39),
E/T ratios necessary for maximal killing were probably not
reached in these assays. Nevertheless, these in vitro data
suggest a potential role for CD4z-expressing neutrophils in
mediating the antitumor effect observed in vivo. We are
currently using the SCID transplant model to investigate
the relative contributions of specific UR-expressing lin-
eages such as NK cells, monocytes, and neutrophils in me-
diating protective tumor immunity in vivo.
Discussion
We have shown that murine SCID long-term repopulat-
ing HSC can be efficiently transduced with the UR CD4z
using a retroviral gene transfer system. Multilineage expres-
sion of CD4z was documented at high levels in myeloid
Figure 4. PCR analysis of sur-
viving mice shows no evidence
of residual Raji-env. Lysates of
PB were prepared from eight
surviving CD4z-transduced mice
challenged with Raji-env at 4
mo after transplant. DNA was
amplified using primers specific
for a 905-bp human endogenous
retroviral sequence (Herv-H) to
detect Raji-env DNA (Mouse PB,
lanes 1–8). Results are compared
to titrations of cultured Raji-env
cells in a background of 104 mu-
rine cells amplified with Herv-H
primers (Raji) and Herv-H–ampli-
fied PB from a control mouse (con).
Samples were amplified with
murine  b-actin primers (447-bp
product) as a positive control
(Mouse PB, lanes 1–3).2267 Hege et al.
and NK cells present in PB and bone marrow, and expres-
sion remained stable over 4–6 mo in vivo. 80% of CD4z-
transplanted mice survived after challenge with a lethal
dose of a disseminated HIV-env–expressing human leuke-
mia, and surviving animals showed no detectable evidence
of residual circulating leukemia cells by PCR analysis. The
data presented here demonstrate that CD4z-expressing ef-
fector cells are the primary mediators of the antitumor ac-
tivity observed, a conclusion supported by the following
observations: (a) Infusion of Raji-p leads to rapid leukemia
dissemination and death of CD4z-expressing mice; (b)
Raji-env cells injected into untransplanted control mice are
lethal; (c) mice transplanted with a poorly expressed UR
(SAbz) succumb after Raji-env challenge; and (d) failure of
CD4z-expressing mice to survive after challenge with Raji-
env cells is associated with the outgrowth of env2 Raji re-
vertants in vivo.
These studies show that a UR that bears the signaling
domain of z can effectively redirect effector cells of non–T cell
lineages both in vivo and in vitro. In contrast to T cells,
FcRs function as the primary immune receptors for mye-
loid and NK cells. Like the TCR-z chain, the g chain of
the FcR mediates intracellular signal transduction (21).
FcgRIIIA (found on macrophages and NK cells) and
FceRI (found on eosinophils, basophils, and mast cells) are
multiunit protein complexes containing cytoplasmic g–g
homodimers or g–z heterodimers that function as connec-
tors to signal transduction (18–20). FcgRI (present on
monocyte/macrophages and activated neutrophils) physi-
cally associates with the homodimeric g subunit of FceRI,
which may act as a signaling intermediate (40, 41). The
genes for the FcR-g and TCR-z chains belong to the same
gene family and share a 34% sequence homology at the
amino acid level (17). The cytoplasmic tails of g and z share
a conserved 18–amino acid immunoreceptor tyrosine motif
that becomes phosphorylated in response to immune re-
ceptor cross-linking by associated tyrosine protein kinases.
Subsequent activation of signal transduction pathways re-
sults in effector functions such as cytolysis, phagocytosis,
and mediator release (18, 42). Although z is functionally as-
sociated with g in a subset of FcRs, and structural similarity
exists between these two chains, URs containing the cyto-
plasmic domain of g rather than z may exhibit enhanced or
differential function in myeloid and NK cells. It will, there-
fore, be of interest in future studies to compare the relative
activity of z- and g-based URs in this SCID model.
Many groups, including our own, have focused on T cell
adoptive immunotherapy approaches to the treatment of
viral infections and cancer. The data presented here, using a
SCID model in which functional lymphocytes are absent,
suggest a possible role for the manipulation of myeloid and
NK cells in the treatment of such diseases. It has been shown
that monocytes from HIV1 patients demonstrate significant
ADCC against HIV-infected T cell targets, and that neu-
trophil and mononuclear cell ADCC is impaired in HIV1
children and adults, suggesting that these effector cells may
be important in the setting of HIV infection (43, 44). Fur-
thermore, neutrophils (37–39), macrophages (45–47), and
NK cells (48) have been shown to mediate efficient ADCC
of tumor cell targets in vitro. FcR-mediated cytotoxicity
can be enhanced by exposure of effector cells to various he-
matopoietic cytokines; for example, neutrophil antitumor
ADCC is upregulated by exposure to G-CSF, GM-CSF,
and IFN-g (37–39), and macrophage antitumor ADCC is
enhanced by M-CSF, GM-CSF, and IL-3 (45–47). In the
SCID transplant model, the CD4z UR is presumably func-
tioning via the FcR-signaling pathway to activate cytotoxic
mechanisms of myeloid and/or NK cells in vivo. It will be
of interest to determine whether UR-mediated effector
function may be enhanced by in vivo exposure of trans-
planted mice to cytokines such as G-CSF or GM-CSF. In
this model, leukemia cells are injected intravascularly into
the same compartment as the gene-modified effector cells,
thereby providing optimal exposure of effectors to tumor.
One of the next challenges will be the development of new
animal models that permit evaluation of the UR stem cell
gene therapy approach in the treatment of established solid
tumors.
Introduction of disease-specific chimeric immune recep-
tors into bone marrow progenitor cells is a novel applica-
tion of HSC gene therapy which, to date, has focused on
gene-marking studies, introduction of chemotherapy and
HIV-1 resistance genes, and correction of rare single-gene
defects (49, 50). This is the first study demonstrating the ef-
ficacy of such an HSC-based immunotherapy approach in
an in vivo model. Gene modification of HSC may be pref-
erable to modification of terminally differentiated effector
cells, such as T or NK cells, for several reasons: (a) multiple
effector cells can be simultaneously redirected using a stem
Figure 5. CD4z-expressing neutrophils lyse Raji-env targets in vitro.
Cytotoxicity assays were performed using neutrophils isolated from
CD4z-transplanted or control mice as effectors and Raji-p or Raji-env
cells as targets. E/T ratios were corrected for the percentage of the bulk
neutrophil population expressing CD4z by FACSÒ analysis. FcR-medi-
ated ADCC was measured by incubation of neutrophils with Raji-p in
the presence of polyclonal anti–human lymphocyte serum. Maximal cy-
tolysis of Raji-env cells by CD4z-expressing neutrophils in three experi-
ments was 10%, 9%, and 8% at corrected E/T ratios of 20:1, 30:1, and 25:1,
respectively. Background cytolysis by controls (CD4z neutrophils1Raji-p
and untransduced (ctrl) neutrophils1Raji-env) was always ,1%, even at
E/T ratios as high as 400:1.2268 Tumor Immunity in SCID Mice with Gene-modified Bone Marrow
cell approach; (b) prolonged in vitro expansion of gene-
modified cells, which may negatively impact their in vivo
trafficking or function, can be avoided; and (c) a renewable
source of gene-modified effector cells capable of prolonged
antigen-specific immune surveillance may be created. Al-
though the UR model system we have used is targeted to
the HIV protein gp120, chimeric immune receptors may
be tailored to recognize a variety of viral or tumor-associ-
ated antigen targets. This stem cell gene therapy approach
could potentially have broad applicability to the field of tar-
geted immunotherapy of malignant disease.
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